Penile Prosthesis Implantation as First-Line Surgery in Peyronie’s Disease with or without ED

Author:

Krishnappa Pramod1ORCID,Moncada Ignacio2,Zaccaro ClaudiaORCID,Fraile Augustin,Otero Javier Romero3ORCID,Martinez-Salamanca Juan,Lledo-Garcia Enrique

Affiliation:

1. NU Hospitals

2. Department of Urology, Hospital La Zarzuela, Madrid, Spain

3. Hm Sanchinarro

Abstract

Abstract Penile prosthesis (PP) in Peyronie’s disease (PD) is considered only when pharmacotherapy has failed in management of erectile dysfunction (ED). Patients with PD who underwent PP (malleable or inflatable) with or without additional maneuvers like manual modeling and grafting from 2012 to 2022 were included in the study. Patient and partner satisfaction were assessed using a 5-point Likert scale. ED was assessed using a validated questionnaire. A total of 168/636 patients underwent PP as first-line surgical management for PD and were included in the study. The mean age was 56.3 years +/- 12.4 and a median BMI of 27.2. Mean follow-up was 56 months (95% CI: 11-21). All 168 patients had undergone additional maneuvers such as manual modeling in 85.7% and grafting in 14.3%. Majority of the patients underwent a 3-piece inflatable PP (86.9%). Thirty-three (19.7%) PD patients without ED had undergone PP. The satisfaction of PD patients with ED and without ED was not statistically different (88.9% vs 87.9%). If surgery is offered in PD, PP may be considered as a first-line surgical treatment regardless of the ED in view of the acceptable complications and high satisfaction rates.

Publisher

Research Square Platform LLC

Reference31 articles.

1. Peyronie's disease;Taylor FL;Urol Clin North Am,2007

2. Deformity stabilization and improvement in men with untreated Peyronie's disease;Berookhim BM;BJU Int,2014

3. An analysis of the natural history of Peyronie’s disease;Mulhall JP;J Urol,2006

4. The etiology of Peyronie’s disease: pathogenesis and genetic contributions;Sharma KL;Sex Med Rev,2020

5. Medical Management of Peyronie's Disease: Review of the Clinical Evidence;Teloken P;Med Sci (Basel),2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3